Currently hemophilia treatment is focused on replacement of clotting factor – having the right amount of clotting factor at the right time for the patient – and patient adherence to a personalized treatment plan. Because the specialty medications used to treat hemophilia are biologic drugs, prescriptions are written in a manner that does not follow traditional drug dosing. In addition, pharmacies may dispense extra doses for breakthrough bleeds. If the patient already has extra doses on hand, sending additional doses is wasteful and costly. The management of clotting factor, known as assay management and dose/adherence management, can help to reduce waste and avoid unnecessary health care costs.